Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company (SCLX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 8-K, registration statements, proxy materials and other key documents filed with the U.S. Securities and Exchange Commission. Scilex is an emerging growth company focused on non-opioid pain management products and related pipeline candidates, and its filings give detailed insight into corporate actions, financing structures and strategic agreements.
For investors tracking Scilex’s capital structure, recent Form 8-K reports describe warrant inducement agreements, exercises of existing warrants, issuance of new unregistered warrants, and the terms of non-recourse loan and securities pledge agreements with The St. James Bank & Trust Company Ltd. These filings outline interest rates tied to the 12-month Secured Overnight Financing Rate, maturity dates, pledged collateral (including Scilex and Datavault AI shares), events of default, and lender remedies.
Filings also document Scilex’s Datavault AI transactions, including a Securities Purchase Agreement for Datavault common stock and a pre-funded warrant, and a License Agreement granting Scilex a worldwide, exclusive license to Datavault patents and know-how for biotech, biopharma, genetic, diagnostic and data-related markets. The associated 8-Ks summarize consideration, royalty structures, milestones and termination conditions.
Scilex’s registration statements, such as its S-1 filing, and proxy statements (DEF 14A) provide further detail on equity incentive plans, option repricing proposals, voting rights for common and preferred stock, and governance matters. These documents complement the company’s periodic reports by explaining how management structures compensation and seeks shareholder approvals for key actions.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting material agreements, financial obligations, equity issuances, and risk disclosures. Users can quickly locate information on warrant terms, loan covenants, Datavault-related agreements, and other items that shape Scilex’s financial profile and strategic direction, without manually parsing every page of each filing.
Director Chun Jay received a grant of a nonstatutory stock option to purchase 20,000 shares of common stock with an exercise price of
Insider option grant and vesting conditions. The CEO and President, Ji Henry, received an incentive stock option to buy 120,000 shares of Scilex Holding Co common stock at
Reporting person: Followwill Dorman, a director of Scilex Holding Co (SCLX), received a nonstatutory stock option grant. The option gives the right to buy 20,000 shares of common stock at an exercise price of
The option vests monthly at a rate of
Scilex Holding Company reported a leadership change, appointing Stephen Ma as Chief Operating Officer, effective October 1, 2025. Ma, age 53, has been the Company’s Chief Financial Officer and Senior Vice President since September 2023 and Corporate Secretary since March 2024, and he joined the board of directors in September 2025.
His background includes more than 15 years of finance and operational experience at multiple pharmaceutical and biotechnology companies, including prior roles at Semnur Pharmaceuticals, Anwita Biosciences, Semnur Inc., Globavir, Ardelyx, PDL BioPharma and Hyperion Therapeutics. Scilex states there are no family relationships or related-party transactions requiring disclosure, no special arrangements for his selection, and his compensation remains unchanged in connection with his appointment as Chief Operating Officer.
Scilex Holding Company entered into a Securities Purchase Agreement with Datavault AI Inc. under which Datavault will issue 15.0 million shares of its common stock and a pre-funded warrant to buy 263,914,094 additional shares for an aggregate purchase price of $150 million.
On September 26, 2025, Datavault issued the initial 15.0 million shares to Scilex at a per share price of $0.5378, paid in Bitcoin based on the Coinbase.com spot rate the prior trading day. After Datavault obtains required stockholder approval, including an increase in authorized common stock up to 1.5 billion shares, it will issue Scilex a pre-funded warrant for 263,914,094 shares with an exercise price of $0.0001 per share in exchange for approximately $141.9 million.
The warrant will be immediately exercisable upon issuance, carry anti-dilution adjustments for stock splits and dividends, and entitle Scilex to participate in rights offerings and dividends as if the warrant were exercised. The Datavault securities are being offered under Datavault’s effective shelf registration statement on Form S-3.
Scilex Holding Company and Scilex, Inc. filed a Schedule 13D reporting combined beneficial ownership of 188,554,849 shares of Semnur Pharmaceuticals, Inc. common stock, representing 79.89% of the outstanding common shares (based on 236,021,088 shares outstanding as of September 25, 2025). Including 5,423,606 shares of Series A Preferred Stock held by SHC (voting on an as-converted basis), the reporting persons control 80.34% of the issuer's total voting power.
The filing explains the ownership arose from a business combination completed September 22, 2025, related debt-equity exchanges (SHC contributed $54,236,058 of outstanding indebtedness in exchange for 5,423,606 preferred shares and received 542,361 common shares), conversion of a $124,883.82 convertible note into 12,488 common shares, and other transactions. The filing also discloses a resale of 12,500,000 shares to Biconomy at $16.00 per share payable in Bitcoin and contract rights giving SHC director designation rights and veto-like protections over certain corporate actions.
Scilex Holding Company entered into a Securities Purchase Agreement with Biconomy PTE.LTD to sell 12,500,000 shares of Semnur Pharmaceuticals common stock, a majority-owned subsidiary, at $16.00 per share, with the purchase price payable in Bitcoin based on a Coinbase spot rate. The shares consist of 554,849 Semnur shares held by Scilex Holding Company and 11,945,151 shares held by Scilex, Inc., and the transaction closed on September 25, 2025. Under the agreement, Semnur must file a registration statement within 90 days to register Biconomy’s resale of these shares. The company also furnished a press release about the deal and filed supplemental risk factor disclosures to update prior public filings.
Scilex Holding Company reported board changes tied to a previously announced business combination involving its subsidiary Semnur Pharmaceuticals and Denali Capital Acquisition Corp. Directors Annu Navani and Jaisim Shah resigned on September 22, 2025, and the company stated their resignations were not due to disagreements over operations, policies or practices.
At the same time, Scilex entered into a Consulting Agreement with Inform LLC, an entity affiliated with Mr. Shah. Inform LLC will provide consulting services for five years for a $50,000 monthly fee. Following the resignations, the board size decreased from six to five directors, and Chief Financial Officer and Senior Vice President Stephen Ma was appointed to fill the resulting vacancy. The company noted Mr. Ma has no family relationships with other leaders and no related party transactions requiring disclosure.
Scilex Holding Co. and related reporting persons disclosed multiple dispositions of Semnur Pharmaceuticals, Inc. (SMNR) common stock executed under a Securities Purchase Agreement. The filing reports dispositions on 09/23/2025: a sale of 11,945,151 shares at a reported price of $16, an additional sale of 554,849 shares at $16, and indirect ownership reported of 6,250,000 shares by Scilex Bio, Inc. The filing shows an aggregate indirect beneficial ownership figure of 181,804,849 shares following one reported transaction. The purchase price for the transactions was stated to have been paid in Bitcoin based on the Coinbase spot rate at 8:00 p.m. New York time on the trading day before closing.
Denali Capital Acquisition Corp. (SMNR) Form 3 reports initial beneficial ownership by Scilex-related entities following a business combination that closed under an amended merger agreement. Scilex, Inc. indirectly holds 193,750,000 shares of Denali Common Stock, Scilex Bio, Inc. holds 6,250,000 shares, and Scilex Holding Company directly holds 1,054,849 shares. The largest block reflects an exchange of Old Semnur shares into Denali Common Stock at an exchange ratio of 1.25 to 1. The filing documents share origins: exchanges from Series A Preferred, a pre-combination purchase, and conversion of a promissory note.